General Information of Drug (ID: DMMU2BZ)

Drug Name
2-(4-aminophenylsulfonamido)acetic acid
Synonyms
5616-30-8; (4-Amino-benzenesulfonylamino)-acetic acid; 2-(4-aminophenylsulfonamido)acetic acid; 2-[(4-aminophenyl)sulfonylamino]acetic acid; CHEMBL285053; (4-aminophenylsulfonylamino)acetic acid; Glycine, N-[(4-aminophenyl)sulfonyl]-; 2-(4-aminobenzenesulfonylamino)ethanoic acid; Sulfanilamidoacetic acid; 2-(4-aminophenylsulfonamido)aceticacid; AC1L92ZE; SCHEMBL1228868; N-4-aminobenzenesulfonyl glycine; CTK1F5176; DTXSID30328582; ((4-aminophenyl)sulfonyl)glycine; BPJUMYMTQYMSFZ-UHFFFAOYSA-N; ZINC1670307
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 230.24
Logarithm of the Partition Coefficient (xlogp) -0.2
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 6
Chemical Identifiers
Formula
C8H10N2O4S
IUPAC Name
2-[(4-aminophenyl)sulfonylamino]acetic acid
Canonical SMILES
C1=CC(=CC=C1N)S(=O)(=O)NCC(=O)O
InChI
InChI=1S/C8H10N2O4S/c9-6-1-3-7(4-2-6)15(13,14)10-5-8(11)12/h1-4,10H,5,9H2,(H,11,12)
InChIKey
BPJUMYMTQYMSFZ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
412201
CAS Number
5616-30-8
TTD ID
D01UNC

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aldose reductase (AKR1B1) TTFBNVI ALDR_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Aldose reductase (AKR1B1) DTT AKR1B1 1.08E-20 0.94 1.58
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Design and synthesis of N-(3,5-difluoro-4-hydroxyphenyl)benzenesulfonamides as aldose reductase inhibitors. Bioorg Med Chem. 2008 Apr 1;16(7):3926-32.